Supporting this concept, we have explored the epigenome and transcriptome of CLL B cells from patients before, during, and after the ibrutinib treatment and demonstrated that the BCR signaling pathway in leukemic B cells regulates APOBEC3 genes expression via direct regulation of their enhancers. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.